| Author | Year | Study type | Quality rating | Population | Outomes measured | Effect size | Confidence intervals / p values | Comments |
|--------------------|------|---------------|-------------------|---|----------------------------------|---|--|--|
| Adults | · | | | | | | | |
| Evans ¹ | 1997 | Crossover | ++ | 62 patients aged 18-97 (mean 38.8). Sympotmatic despite 800-1000 μg inhaled corticosteroids. Mean FEV1 75% pred. (35-116%) 15% reversibility to b 2 agonists. Compared 800m g inh BUDE + low dose theoph OR 1600 μg inh BUDE. Study period of 3 months. | FVC FEV1 PEF Use of b 2 agonists | 800µg BUDE plus theoph resulted in FVC and FEV1 <10% increase from baseline PEF increased in both groups ,25 l/min Reduced in both groups by ≈1 puff / 24 hrs | NS difference between treatments NS difference between treatments | In patients with persistent symptoms on up to 1mg/day inhaled budesonide, adding low dose oral theoph (serum conc <10m g/l provided similar improvements in lung function, symptom control and b 2 agonist use to doubling the dose of inhaled corticosteroid to 1.6 mg/day. |
| Ukena ² | 1997 | RCT | + | 133 patients | Increase in | ≈ 20% | P<0.01 NS | In asthmatic |

1 of 3

| | | | | aged 18-70 (mean 48.5) symptomatic despite 400m g BDP/day. FEV1 50-85% pred. 15% reversibility to b 2 agonists. Compared 400 µg inh BDP + low dose theoph OR 800 µg inh BDP. Study period of six weeks | Reduction in PEF variability | am/pm PEF in both groups ≈ 30% in both groups ≈ 10% FEV1 in both treatments Improved signigicantly in both groups | between treatments. P<0.01 NS difference between treatments. P<0.01 NS difference between treatments. P<0.01 NS difference between treatments. P<0.001 NS difference between treatments. | patients not controlled by 400 mg/day BDP, doubling the dose of BDP or adding theophylline provided equivalent improvements in asthma symptoms, lung function, and. b 2 agonist use. Similar adverse events profile except that theoph. Associated more with mild GI symptoms. |
|-------------------------------|------|------------------|---|--|------------------------------------|--|--|--|
| Children Nassif ³ | 1981 | Crossover RCT | + | 33 children aged 7-19. Comparison of theoph vs placebo in steroid dependent asthma with subgroups of 21 patients on 200-900 µg / day inhaled BDP (mean 530 µg / day) and 11 patients on alternate day prednisolone (mean dose 33 | PEF Spriometry Asthma symptoms | PEF increased in inhaled BDP and oral prednisolong group. FEV1 increased in both groups. Patients were free of all symptoms 63%(+6,-6) of days cmpared | P0.02 before bronchodilator and p<0.05 after. P<0.01 | In children with asthma on inhaled or oral corticosteroids, treatment with theophylline can improve the frequency and severity of asthma symptoms and improve lung function. Although there is evidence of reduced use of rescue steroid medication for exacerbations, |

2 of 3 09/05/2018, 11:48

| mg/day). Study period of 2 months. | aqgonist Rescue with additional | ľ | P=0.02 | no assessment of a true steroid sparing effect is made. |
|--|----------------------------------|---|--------|---|
| | | Additional daily corticosteroids were needed 3 times as often with placebo. | | |

- Evans DJ, Taylor DA, Zetterstrom O, Chung KF, O'Connor BJ, Barnes PJ. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med 1997;337(20):1412-8.
- 2. Ukena D, Harnest U, Sakalauskas R, Magyar P, Vetter N, Steffen H, et al. Comparison of addition of theophylline to inhaled steroid with doubling of the dose of inhaled steroid in asthma. Eur Respir J 1997;10(12):2754-60.
- 3. Nassif EG, Weinberger M, Thompson R, Huntley W. The value of maintenance theophylline in steroid-dependent asthma. N Engl J Med 1981;304(2):71-5.

3 of 3